In Prof. Drake’s laboratory, they are applying a variety of mass spectrometry-based approaches to identify molecular diagnostic and prognostic biomarkers of cancer. Their emphasis is on the application for imaging mass spectrometry analysis of clinically derived tissues, fluids and exosomes to develop proteomic-based or small molecule diagnostic assays, with a particular focus on glycosylation and its role in disease.
VIDEO：interview -- Richard Drake, Using MALDI imaging to study protein glycosylation patterns in cancer
A new state-of-the-art, translational MALDI Imaging Research Center has been created. The facility is anchored by a dual-source Bruker 7T solariX FT-ICR mass spectrometer, as well as a new rapifleX TissueTyper MALDI-TOF, autofleX III MALDI-TOF and an HTX TM sprayer. These projects combine the capabilities of the MUSC Proteomics Center with clinical research, lipidomic, biorepository and molecular pathology resources, as well as strong collaborations with other Center principal investigators. Current types of cancer being targeted include prostate, breast, liver, colon, kidney, lung and pancreatic cancers.
50
0
